QLGN's free cash flow for Q4 2023 was $-5.70M. For the 2023 fiscal year, QLGN's free cash flow was decreased by $3.11M and operating cash flow was $-5.70M. See a summary of the company’s cash flow.

Cash Flow	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Mar 20
Operating Cash Flow	$ -13.55M	$ -10.30M	$ -13.25M	$ -14.73M	$ -10.16M	$ 57.33K
Investing Cash Flow	$ -255.39K	$ 4.22M	$ -183.76K	$ -141.36K	$ -65.09K	$ -194.48K
Financing Cash Flow	$ 2.79M	$ -550.00K	$ 2.91M	$ 8.43M	$ 34.05M	$ 165.14K
Cash Flow From Discontinued Operation	-	-	-	-	-	-
Other Cash Adjustment Inside Changein Cash	-	-	-	-	-	-
End Cash Position	$ 13.00M	$ 401.80K	$ 7.02M	$ 17.54M	$ 23.98M	$ 153.12K
Income Tax Paid Supplemental Data	$ 9.03K	$ 5.57K	$ 5.57K	$ 5.13K	$ 4.77K	$ 5.28K
Interest Paid Supplemental Data	-	-	-	$ 1.23K	$ 32.69K	$ 91.56K
Issuance Of Capital Stock	-	-	-	-	$ 34.01M	$ 0.00
Issuance Of Debt	$ -110.00K	$ -550.00K	-	$ -138.74K	$ 1.39M	$ 331.06K
Repayment Of Debt	$ -110.00K	$ -550.00K	-	$ -138.74K	$ -1.32M	$ -165.92K
Free Cash Flow	$ -13.88M	$ -10.30M	$ -13.41M	$ -14.87M	$ -10.38M	$ -137.15K
Domestic Sales	-	-	-	-	-	-
Foreign Sales	-	-	-	-	-	-

Currency in USD

Qualigen Therapeutics Cash Flow

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing